Cereno Scientific AB (CRNO.B)

Overview

Cereno Scientific AB (publ) is a pioneering clinical stage biotechnology company focused on the global development of new therapies for the treatment of cardiovascular and rare diseases. Leveraging its expertise in epigenetic modulation, Cereno Scientific is at the forefront of creating innovative treatments that aim to address unmet medical needs in these critical areas. Founded in 2012 and based in Gothenburg, Sweden, the company embodies a commitment to advancing healthcare through scientific excellence and strategic collaborations. With its ongoing clinical trials and robust preclinical development program, Cereno Scientific is dedicated to transforming the therapeutic landscape for patients worldwide.

Products and Services

CS1: Cereno Scientific’s flagship product candidate, currently in phase II clinical trial, is designed to treat pulmonary arterial hypertension (PAH), a rare and life-threatening disease. As a histone deacetylase (HDAC) inhibitor, CS1 showcases a multifaceted mechanism of action, offering potential benefits such as pressure reduction, reverse remodeling, anti-inflammatory, anti-fibrotic, and antithrombotic effects. This holistic approach to treatment sets CS1 apart as a promising therapeutic option for PAH patients.

Preclinical Drug Candidates (CS585 and CS014): These compounds represent Cereno Scientific’s innovative efforts in tackling cardiovascular diseases at the preclinical stage. Developed in collaboration with the University of Michigan, both CS585 and CS014 are being explored for their potential to offer novel treatment paths for cardiovascular conditions. The collaboration emphasizes a shared vision towards identifying and advancing leading-edge therapeutic solutions.

Collaboration with Abbott: In a strategic move to enhance its research and development capabilities, Cereno Scientific has entered into an agreement with Abbott for the use of the CardioMEMS HF System. This collaboration aims to leverage Abbott’s pioneering technology to bolster Cereno Scientific’s drug development processes, particularly in the cardiovascular domain, thereby enhancing the precision and effectiveness of its therapeutic offerings.